No change in residual viremia after switch to 2-drug regimen.

In the ASPIRE trial patients on antiretroviral therapy (ART)
with three drugs and suppressed viremia were randomized
to continue their present ART or to switch to a combination
of dolutegravir and lamivudine.

Read more